Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Praziquantel

FDA-approved product (tablet, oral), marketed as Biltricide, Praziquantel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Praziquantel
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Helminthiasis
  • Infection
  • Opisthorchiasis
  • Schistosomiasis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Quinoline derivatives and related substances
FDA pharmacologic class
Anthelmintic FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P02BA01; FDA class Anthelmintic

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Praziquantel in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Praziquantel with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis

    NCT00510159 · start 2007-08

    Registered record
    Registry ID
    NCT00510159
    Conditions
    Schistosoma Haematobium
    Interventions
    Artesunate+Sulfamethoxypyrazine/pyrimethamin; Praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2007-08
    Completion
    2007-12
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosoma Haematobium
    InterventionArtesunate+Sulfamethoxypyrazine/pyrimethamin; Praziquantel
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Schistosome and Intestinal Worm Infections and Malaria Morbidity Among School and Pre-school Children in, Tanzania

    NCT00347113 · start 2006-07

    Registered record
    Registry ID
    NCT00347113
    Conditions
    Anaemia; Malaria; Hepatosplenomegaly
    Interventions
    Albendazole and praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-07
    Completion
    2011-01
    Enrolment
    620

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaemia; Malaria; Hepatosplenomegaly
    InterventionAlbendazole and praziquantel
    PhaseNot applicable
    Registry statusCompleted

  • Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil

    NCT00403611 · start 2006-03

    Registered record
    Registry ID
    NCT00403611
    Conditions
    Schistosomiasis Mansoni
    Interventions
    Praziquantel 60 mg/kg; Praziquantel 40 mg/kg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-03
    Completion
    2008-05
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosomiasis Mansoni
    InterventionPraziquantel 60 mg/kg; Praziquantel 40 mg/kg
    PhasePhase 4
    Registry statusCompleted

  • The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda

    NCT00215267 · start 2005-09

    Registered record
    Registry ID
    NCT00215267
    Conditions
    Schistosomiasis; Malaria
    Interventions
    praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-09
    Completion
    2007-10
    Enrolment
    540

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosomiasis; Malaria
    Interventionpraziquantel
    PhaseNot applicable
    Registry statusCompleted

  • Urogenital Schistosomiasis and Sexually Transmitted Infections in Madagascar

    NCT00713999 · start 2001-08

    Registered record
    Registry ID
    NCT00713999
    Conditions
    Sexually Transmitted Infections; Schistosoma Haematobium
    Interventions
    Treatment with anti-STI and anti-schistosoma regimens
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2001-08
    Completion
    2003-09
    Enrolment
    680

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSexually Transmitted Infections; Schistosoma Haematobium
    InterventionTreatment with anti-STI and anti-schistosoma regimens
    PhaseNot applicable
    Registry statusCompleted